CMPS COMPASS Pathways plc
Trend channel, buy level and 3-month target. Information only, not financial advice.
At the channel floor · 9-month channel rising
Price is on the lower line, where it has held before.
- 9-month channel read from
- US$10.76 – US$16.21 · rising, more than +100% a year
- 12-month channel
- US$11.14 – US$16.20 · rising, more than +100% a year
- Price in channel
- 15% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$16.20
- Turns bearish below
- US$10.76
- Published levels
- Buy and target are not from this channel — see below.
Price history, with the path projected 3 months forward
Updated 10:42 PM ET (15 h ago)
- Daily close
- Upper trend line (9 months)
- Lower trend line (9 months)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Suggested path
Buy now
US$11.57
last close · 30 Oct 2026
Our target
US$16.50
by 28 Jan 2027
Projected move
42.6%
gross, before costs
Last close is our buy.
Target: the projected upper line.
This move size: reached in 41% of 21 past stretches, typically in 90 days. (0.39% per day)
- Upper line touches
- 2
- Lower line touches
- 3
- Fit confidence
- 63%
- Fitted
- 1 Nov 2026
Company information
About COMPASS Pathways plc
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kabir Kumar Nath
- Employees
- 156
- Country
- GB
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$1.54B
- Enterprise value
- —
- Beta
- 2.56
- Avg volume
- 3.22M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 4.88-15.87
- Exchange
- NASDAQ
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.